Nilsson A, Hökfelt B
Acta Endocrinol Suppl (Copenh). 1978;216:83-96.
Seven acromegalic patients were given bromocriptine, starting with 1.25 mg/day, then gradually increased to 20 mg daily, which dosage was continued for 3--9 weeks. Treatment with bromocriptine resulted in a significant fall of systolic and diastolic blood pressure in supine and upright position accompanied by a marked reduction in plasma and urinary noradrenaline but without effect on adrenaline. Plasma renin activity fell during institution of bromocriptine and remained significantly lower during prolonged treatment. Urinary aldosterone showed no significant changes during medication. The plasma noradrenaline response to physical exercise was reduced by bromocriptine treatment, whereas the adrenaline response was unaltered. The plasma catecholamine response to hypoglycemia was not statistically different during bromocriptine as compared to before medication.
7例肢端肥大症患者服用溴隐亭,起始剂量为1.25毫克/天,然后逐渐增加至每日20毫克,该剂量持续服用3至9周。溴隐亭治疗导致仰卧位和直立位的收缩压和舒张压显著下降,同时血浆和尿去甲肾上腺素明显减少,但对肾上腺素无影响。在开始使用溴隐亭期间,血浆肾素活性下降,在长期治疗期间仍显著降低。用药期间尿醛固酮无显著变化。溴隐亭治疗使血浆去甲肾上腺素对体育锻炼的反应降低,而肾上腺素反应未改变。与用药前相比,溴隐亭治疗期间血浆儿茶酚胺对低血糖的反应无统计学差异。